Organisation paid for research Program year 2025 Source: CMS Open Payments

Facey Medical Foundation

Neither a doctor nor a teaching hospital

Research payments

$1,068,676

183 payments

Through program year 2025, Facey Medical Foundation is reported as receiving $1,068,676 in research payments, across 183 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $261,254 57
2024 Research $132,366 14
2023 Research $74,706 4
2022 Research $34,142 8
2021 Research $49,429 30
2020 Research $349,305 40
2019 Research $167,475 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ironwood Pharmaceuticals, Inc $429,218 43 payments
  2. AbbVie, Inc. $256,936 49 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $102,046 45 payments
  4. AstraZeneca Pharmaceuticals LP $92,524 4 payments
  5. Eli Lilly and Company $52,325 5 payments
  6. GlaxoSmithKline, LLC. $49,985 11 payments
  7. Genentech, Inc. $31,665 8 payments
  8. Adare Pharmaceuticals, Inc. $17,369 2 payments
  9. Celgene Corporation $14,608 2 payments
  10. Shire North American Group Inc $11,950 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. C3718-301 $340,294 26 payments
  2. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $211,425 33 payments
  3. McP-103-312 $81,404 13 payments
  4. A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $54,024 2 payments
  5. A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $49,985 11 payments
  6. A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $43,815 3 payments
  7. This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy $38,500 2 payments
  8. vixarelimab ulcerative colitis study $31,665 8 payments
  9. M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $31,345 10 payments
  10. A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Mln9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma $30,463 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record